Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults

Cell-mediated Immunity Study of H1N1 Influenza A Vaccine With Trivalent Inactivated Influenza Vaccine in Healthy Adults

A single center, randomized clinical trial is to be conducted in healthy adults (18-60 years) to evaluate the safety and immunogenicity and study the cell-mediated Immunity of Sinovac's H1N1 influenza A Vaccine (PANFLU.1) with Trivalent Inactivated Influenza Vaccine (ANFLU).

Study Overview

• Status: Completed
• Conditions: Influenza
• Intervention / Treatment: Biological: H1N1 influenza A Vaccine (PANFLU.1); Biological: Trivalent Inactivated Influenza Vaccine (ANFLU)

• Study Type: Interventional
• Enrollment (Actual): 150
• Phase: Phase 4

Contacts and Locations

Study Locations

• China
  • Beijing, China
    • Beijing Centers for Diseases Control and Prevention

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Healthy male or female aged between 18 and 60
2. Be able to show legal identity card for the sake of recruitment
3. Volunteers are able to understand and sign the informed consent

Exclusion Criteria:

1. Cases, cured cases and close contact of influenza A (H1N1) virus
2. History of H1N1 vaccine or seasonal influenza vaccine administration
3. Women of pregnancy, lactation or about to be pregnant in 60 days
4. Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc
5. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
6. Autoimmune disease or immunodeficiency
7. Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids
8. Diabetes mellitus (type I or II), with the exception of gestational diabetes
9. History of thyroidectomy or thyroid disease that required medication within the past 12 months
10. Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years
11. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
12. Active malignancy or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of study

13. Seizure disorder other than:

    • Febrile seizures under the age of two years old
    • Seizures secondary to alcohol withdrawal more than 3 years ago, or
    • A singular seizure not requiring treatment within the last 3 years
14. Asplenia, functional asplenia or any condition resulting in the absence or removal o the spleen
15. Guillain-Barre Syndrome
16. Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
17. History of any blood products within 3 months before the dosing
18. Administration of any other investigational research agents within 30 days before the dosing
19. Administration of any live attenuated vaccine within 30 days before the dosing
20. Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or allergy treatment with antigen injections, within 14 days before the dosing
21. Be receiving anti-TB prophylaxis or therapy currently
22. Axillary temperature > 37.0 centigrade at the time of dosing

23. Psychiatric condition that precludes compliance with the protocol:

    • Past or present psychoses
    • Past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years
    • Disorder requiring lithium
    • Suicidal ideation occurring within five years prior to enrollment
24. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group 1: Day 0-PANFLU.1; Day 21-ANFLU; 50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine; Day 21: 15 μg ANFLU vaccine.	Biological: H1N1 influenza A Vaccine (PANFLU.1); H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm); Biological: Trivalent Inactivated Influenza Vaccine (ANFLU); Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)
Experimental: Group 2: Day 0-ANFLU; Day 21-PANFLU.1; 50 subjects to receive-Day 0: 15 μg ANFLU vaccine; Day 21: 15 μg PANFLU.1 vaccine.	Biological: H1N1 influenza A Vaccine (PANFLU.1); H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm); Biological: Trivalent Inactivated Influenza Vaccine (ANFLU); Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)
Experimental: Group 3: Day 0-PANFLU.1+ANFLU; 50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine+ANFLU vaccine.	Biological: H1N1 influenza A Vaccine (PANFLU.1); H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm); Biological: Trivalent Inactivated Influenza Vaccine (ANFLU); Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Study the cell-mediated immunity of H1N1 vaccine with seasonal influenza vaccine	6 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Evaluate immunogenicity of H1N1 vaccine with seasonal influenza vaccine in adults	3 months
Evaluate safety of H1N1 vaccine with seasonal influenza vaccine in adults	3 months

Collaborators and Investigators

• Sponsor: Sinovac Biotech Co., Ltd

Publications and helpful links

General Publications

• Wu J, Zhong X, Li CK, Zhou JF, Lu M, Huang KY, Dong M, Liu Y, Luo FJ, Du N, Chui C, Liu LQ, Smith NM, Li B, Shi NM, Song LF, Gao Y, Wang DY, Wang X, Zhu WF, Yan Y, Li Z, Chen JT, McMichael AJ, Yin WD, Xu XN, Shu Y. Optimal vaccination strategies for 2009 pandemic H1N1 and seasonal influenza vaccines in humans. Vaccine. 2011 Jan 29;29(5):1009-16. doi: 10.1016/j.vaccine.2010.11.058. Epub 2010 Dec 2.

Study record dates

Study Major Dates

• Study Start: October 1, 2009
• Primary Completion (Actual): December 1, 2009
• Study Completion (Actual): January 1, 2010

Study Registration Dates

• First Submitted: October 29, 2009
• First Submitted That Met QC Criteria: November 3, 2009
• First Posted (Estimate): November 5, 2009

Study Record Updates

• Last Update Posted (Estimate): November 27, 2012
• Last Update Submitted That Met QC Criteria: November 26, 2012
• Last Verified: November 1, 2012

More Information

Terms related to this study

• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Orthomyxoviridae Infections; Influenza, Human; Physiological Effects of Drugs; Immunologic Factors; Vaccines
• Other Study ID Numbers: PRO-PanFlu-4002